Invasive breast cancer risk did not differ significantly in women with a hysterectomy using estrogen-alone therapy when directly comparing different doses, formulations, and routes of delivery to the conventional oral conjugated equine estrogen (CEE), a recent study found. Researchers used data from the Women’s Health Initiative (WHI) observational study. Analyses included 26,525 postmenopausal women with a hysterectomy aged 50-79 years at study entry. They found:
- Average follow-up was 8.2 years.
- For CEE users, no difference was observed between low-dose CEE vs conventional-dose CEE for breast cancer (HR, 0.99).
- Compared with conventional-dose CEE, transdermal estrogen was associated with a nonsignificant lower risk of invasive breast cancer (HR, 0.75).
Shufelt C, Bairey Merz CN, Pettinger MB, et al. Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: Findings from the WHI observational study. [Published online ahead of print May 7, 2018]. Menopause. doi:10.1097/GME.0000000000001115.
Must Reads in Breast Cancer
Gender Images & Social Expectations in BC Diagnosis, Cancer; ePub 2018 Sep 24; Kim, Glassgow, et al
Predicting Mammography Adherence by Income Level, Women’s Health Issues; ePub 2018 Aug 8; Gathirua-Mwangi, et al
Estrogen-alone Therapy & Invasive Breast Cancer, Menopause; ePub 2018 May 7; Shufelt, et al
Missed Breast Cancers in High Risk MRI Screening, Breast Cancer Res Treat; ePub 2018 Jan 31; Vreemann, et al